Effect of short‐term levamisole therapy on delayed hypersensitivity Academic Article Article uri icon

Overview

MeSH Major

  • DNA Methylation
  • Exons
  • Gene Silencing
  • Transcription, Genetic

abstract

  • A randomized trial of short-term Levamisole treatment was undertaken in a cancer population unresponsive to dinitrochlorobenzene (DNCB) to determine whether this agent increased delayed hypersensitivity. Of 100 patients entered, 50 received Levamisole (150 mg daily x 3) during DNCB challenge. The other 50 patients were challenged but not given the drug. The conversion rate to DNCB+ was 20% (10/50) for those treated and 12% (6/50) for controls. The difference is not significant. When all 100 patients were considered there was a statistically significant inverse relationship between extent of disease and the incidence of conversion to a DNCB reactive state. Levamisole as given does not appear to have a major influence on delayed cutaneous hypersensitivity.

publication date

  • January 1980

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19800115)45:2<362::AID-CNCR2820450228>3.0.CO;2-1

PubMed ID

  • 6985836

Additional Document Info

start page

  • 362

end page

  • 6

volume

  • 45

number

  • 2